In addition, a phase I trial is evaluating three different weekly intermittent dosing schedules which appear to alleviate these side effects. I inhibitors observed in preclinical models, a phase I trial evaluating irofulven in combination with irinotecan is also in progress. In conclusion, irofulven is an active compound with a novel mechanism of action. Activity in drug-resistant preclinical models and in patients with chemoresistant tumors suggests that irofulven may be useful as monotherapy. In addition, irofulven shows promise in combination therapies with established chemotherapeutic agents.
Side effects seen with irofulven are common to most other chemotherapeutic agents.
Alternate dosing schedules are being evaluated to further enhance the safety and efficacy of irofulven.